WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 920-927

  Xu, Cen ^a,b   Reith, Maarten E A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE DERIVATIVE; COMPLEMENTARY DNA; DOPAMINE TRANSPORTER; MAZINDOL; RADIOLIGAND;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING COMPETITION; BINDING SITE; DISSOCIATION CONSTANT; MODEL; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RAT;

BINDING, COMPETITIVE; CARRIER PROTEINS; CLONING, MOLECULAR; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MODELS, CHEMICAL; NERVE TISSUE PROTEINS; RADIOLIGAND ASSAY; RECOMBINANT PROTEINS; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0030839892     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. 3H]WIN 35,428 binding in the caudate nucleus of the rabbit: Evidence for a single site on the dopamine transporter. J. Pharmacol. Exp. Ther. 273: 435-444, 1995.
2. BERGER, P., ELSWORTH, J. D., REITH, M. E. A., TANEN, D. AND ROTH, R. H.: Complex interaction of cocaine with the dopamine uptake carrier. Eur. J. Pharmacol. 176: 251-252, 1990.
3. BOJA, J. W., MARKHAM, L., PATEL, A., UHL, G. AND KUHAR, M. J.: Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. Neuroreport 3: 247-248, 1992.
4. BUCK, K. J. AND AMARA, S. G.: Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 91: 12584-12588, 1994.
5. 3H]cocaine in striatum and its relationship to the dopamine transporter, Membr. Biochem. 7: 87-106, 1987.
6. CARROLL, F. I., LEWIN, A. H., BOJA, J. W. AND KUHAR, M. J.: Cocaine receptor. Biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem. 35: 969-981, 1992.
7. 3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J. Neurosci. Methods 51: 23-30, 1994.
8. DELEAN, A., MUNSON, P. J. AND RODBARD, D.: Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235: E97-E102, 1978.
9. 3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains. Neurochem. Res. 19: 201-208, 1994.
10. EHLERT, F. J.: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33: 187-194, 1988.
11. 3H]GBR 12935 to rat and bovine striata. Membr. Biochem. 10: 129-144, 1993.
12. ESHLEMAN, A. J., NEVE, R. L., JANOWSKY, A. AND NEVE, K. A.: Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 274: 276-283, 1995.
13. 3H]cocaine binding sites in monkey brain. Soc. Neursci. Abstr. 15: 1090, 1989.
14. GIROS, B. AND CARON, M. G.: Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14: 43-49, 1993.
15. GIROS, B., EL MESTIKAWY, S., GODINOT, N., ZHENG, K., HAN, H., YANG-FENG, T. AND CARON, M. G.: Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42: 383-390, 1992.
16. GIROS, B., WANG, Y. M., SUTER, S., MCLESKEY, S. B., PIFL, C. AND CARON, M. G.: Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269: 15985-15988, 1994.
17. Gu, H., WALL, S. C. AND RUDNICK, G.: Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269: 7124-7130, 1994.
18. 3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26: 35-44, 1984.
19. JONES, S. R., GARRIS, P. A., KILTS, C. D. AND WIGHTMAN, R. M.: Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat. J. Neurochem. 64: 2581-2589, 1995.
20. KITAYAMA, S., SHIMADA, S., XU, H., MARKHAM, L., DONOVAN, D. M. AND UHL, G. R.: Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA 89: 7782-7785, 1992.
21. KRUEGER, B. K.: Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55: 260-267, 1990.
22. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol. Pharmacol. 36: 518-524, 1989.
23. MAY, L. J., KUHR, W. G. AND WIGHTMAN, R. M.: Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry. J. Neurochem. 51: 1060-1069, 1988.
24. MCELVAIN, J. S. AND SCHENK, J. O.: A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43: 2189-2199, 1992.
25. MEIERGERD, S. M. AND SCHENK, J. O.: Kinetic evaluation of the commonality between the site(s) of action of cocaine and some other structurally similar and dissimilar inhibitors of the striatal transporter for dopamine. J. Neurochem. 63: 1683-1692, 1994.
26. PIFL, C., GIROS, B. AND CARON, M. G.: Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13: 4246-4253, 1993.
27. 3H]GBR 12,935 binding. Mol. Pharmacol. 45: 125-135, 1994.
28. 3H]tropane to the dopamine uptake carrier. J. Neurochem. 61: 167-177, 1993.
29. REITH, M. E. A., DE COSTA, B., RICE, K. C. AND JACOBSON, A. E.: Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur. J. Pharmacol. 227: 417-425, 1992.
30. REITH, M. E. A., MEISLER, B. E., SERSHEN, H. AND LAJTHA, A.: Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 35: 1123-1129, 1986.
31. REITH, M. E. A. AND SELMECI, G.: Radiolabeling of dopamine uptake sites in mouse striatum: comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn Schmiedebergs Arch. Pharmacol. 345: 309-318, 1992.
32. 3H]WIN 35,428) binding. Biochem. Pharmacol. 52: 1436-1446, 1996.
33. RICHELSON, E. AND PFENNING, M.: Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 104: 277-286, 1984.
34. RITZ, M. C., LAMB, R. J., GOLDBERG, S. R. AND KUHAR, M. J.: Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223, 1987.
35. 125I]RTI-55. J. Pharmacol. Exp. Ther. 270: 296-309, 1994.
36. SEGEL, I. H.: Simple inhibition systems. In Enzyme Kinetics, Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme System, pp. 100-159, John Wiley & Sons, New York, 1975.
37. SHANK, R. P., GARDOCKI, J. F., SCHNEIDER, C. R., VAUGHT, J. L., SETLER, P. E., MARYANOFF, B. E. AND MCCOMSEY, D. F.: Preclinical evaluation of McN-5707 as a potential antidepressant. J. Pharmacol. Exp. Ther. 242: 74-84, 1987.
38. TOMLINSON, G. AND HNATOWICH, M. R.: Apparent competitive inhibition of radioligand binding to receptors: experimental and theoretical considerations in the analysis of equilibrium binding data. J. Recept. Res. 8: 809-830, 1988.
39. 125I]iodophenyl)tropane binding. Mol. Pharmacol. 43: 264-270, 1993.
40. WIENER, H. L. AND REITH, M. E. A.: Determination of radioligand specific activity using competition binding assays. Anal. Biochem. 207: 58-62, 1992.
41. WISE, R. W.: Neural mechanism of the reinforcing action of cocaine. In Cocaine: Pharmacology, Effects and Treatment of Abuse, ed. by J. Grabowski, p. 15. NIDA Research Monograph 50, U.S. Government Printing Office, Washington, D.C. 20402, 1984.
42. 3H] WIN 35,428 Binding to the human dopamine transporter in a similar fashion. J. Neurochemistry, in press, 1997.
43. XU, C., COFFEY, L. L. AND REITH, M. E. A.: Translocation of dopamine and binding of 2β-carbomethoxy-3β-(4-fluorophenyl)tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem. Pharmacol. 49: 339-350, 1995.
44. 3H]WIN 35,428 binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 355: 64-73, 1997.
45. XU, C. AND REITH, M. E. A.: Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: Is the bioactive form positively charged or neutral? J. Pharmacol. Exp. Ther. 278: 1340-1348, 1996.